Filter By Category
Archives
Share on -
CIFORADENANT
Generic Name: CIFORADENANT
ABSTRACT -
Ciforadenant (CPI-444) is an oral, selective adenosine A2A receptor (A2AR) antagonist developed by Corvus Pharmaceuticals for solid tumour immunotherapy. Tumours generate immunosuppressive adenosine in the tumour microenvironment (TME) via CD39/CD73 ectonucleotidases; adenosine binding to A2AR on T cells and NK cells suppresses anti-tumour immunity. By blocking A2AR, ciforadenant aims to restore immune cell activity in the TME. Phase I/II trials evaluated it in combination with atezolizumab (anti-PD-L1) in renal cell carcinoma and other solid tumours.
DOSAGE -
Oral tablet; 100 mg twice daily in combination with atezolizumab in Phase I/II trials; dose and schedule under optimisation.
SIDE EEFECTS -
- Fatigue
- Nausea
- Anaemia
- Diarrhoea
- Elevated liver enzymes
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Skin rash
- Drug hypersensitivity
- Urticaria
- Angioedema (rare)
DRUG INTERACTIONS-
- Additive immune activation with PD-1/PD-L1 checkpoint inhibitors (combination under study)
- CYP3A4 interactions likely — monitor with narrow therapeutic index drugs
- Methylxanthines (caffeine, theophylline): additive A2A pathway modulation
PREAUTONS–
- Limit caffeine and xanthine-containing beverages during treatment (A2A receptor interaction)
- Effective contraception required
- LFT monitoring recommended
- Autoimmune conditions may be exacerbated
WARNINGS –
- Immune-mediated adverse events may be amplified when combined with checkpoint inhibitors
- Embryo-foetal toxicity not excluded
- Not approved — use restricted to clinical trial setting
Share on -
. Developed by